All In Biotech

Drug Trial Radar · NCT05173792

Study of AK119 in Subjects With Advanced Solid Tumors

A Phase I, Multicenter, Open-Label, Dose-escalation and Dose-exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of of AK119 (CD73) in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Dec 22, 2021

Primary completion

May 22, 2023

Study completion May 22, 2023

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Dec 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.

Conditions

  • Solid Tumor

Interventions

  • AK119Drug

    Subjects will receive AK119 intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
  2. Number of participants with a Dose Limiting Toxicity (DLT)Time frame: During the first 4 weeks in dose-escalation phase, during the first 3 weeks in dose-exploration phase

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fudan University Zhongshan Hospital

    Shanghai, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.